Osimertinib plus chemotherapy in uncommon EGFRm NSCLC

Trial Identifier: D5161C00017
Sponsor: AstraZeneca
Start Date: January 2022
Primary Completion Date: March 2023
Study Completion Date: March 2023
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese (Simplified) Translation

Trial Locations

Country Location
CN Chengdu, CN, 610041
CN Harbin, CN, 150049
CN Mianyang, CN, 621000
CN Nan Chong, CN, 637000
CN Yibin, CN, 644000
CN Zhengzhou, CN, 450000